JNJ vs DXCM
By Alex · Tickerpine
Johnson & Johnson vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DXCM |
|---|---|---|
| Price | $263.81 | $77.94 |
| Market cap | $635.07B | $29.41B |
| P/E ratio | 40.0 | 30.9 |
| ROE | 20.02% | 38.49% |
| Profit margin | 16.20% | 20.12% |
| Revenue growth | 5.90% | 13.10% |
| Dividend yield | 2.03% | 0.00% |
| Beta | 0.21 | 1.48 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DXCM in plain English
- JNJ is the bigger company — about 21.6× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 30.9 vs 40.0).
- DXCM earns a higher return on equity (38% vs 20%).
- DXCM is growing revenue faster (13% vs 6%).
- JNJ pays a dividend (2.03%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.